Kicking Off With KRAS in NSCLC

Now Viewing

EP: 1.Kicking Off With KRAS in NSCLC

EP: 2.Enthusiasm With EGFR Exon 20+ in NSCLC

EP: 3.What’s Next in HER2+ and Exon 19 Deletions in NSCLC?

EP: 4.ASCO 2021 Updates With Neoadjuvant Immunotherapy in NSCLC

EP: 5.Circling the Latest With ctDNA in Lung Cancer

Good evening and welcome! Thank you for joining OncLive’s third episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.

Live from New York City, I’m Josh Sabari, MD, an assistant professor in the Department of Medicine at NYU Grossman School of Medicine, and it’s great to be back on this program, this time as your host!

But it’s not just me tonight. Virtually joining me tonight is Dr Jamie Chaft, associate professor and thoracic medical oncologist at Memorial Sloan Kettering Cancer, and Dr Vamsidhar Velcheti, associate professor and director of thoracic medical oncology and at NYU Langone’s Perlmutter Cancer Center. Welcome to you both and it’s an honor to share this virtual stage with you!

Tonight’s discussion is going to focus on novel targeted therapeutics in KRAS as well as EGFR exon 20 insertion mutations; and neoadjuvant breakthroughs in lung cancer presented at the 2021 ASCO Annual Meeting. We’re also going to discuss some intriguing data with circulating tumor DNA that was presented at this year’s conference.

Let’s kick this show off!

Funding provided by Daiichi Sankyo/Content Developed Independently by OncLive